Seraphim Awarded 'Top Performer' in Kiwa PVEL's 2025 PV Module Reliability Scorecard for Sixth Time
Through its rigorous Product Qualification Program (PQP), Kiwa PVEL subjects PV modules to a series of demanding tests, including Thermal Cycling (TC600), Damp Heat (DH2000), Potential Induced Degradation (PID), Light Induced Degradation (LID) combined with Light and Elevated Temperature Induced Degradation (LETID), and PAN (Performance After Normalization) analysis. These comprehensive assessments evaluate the modules' reliability and performance across multiple dimensions. In this year's evaluation, Seraphim's Sable series TOPCon modules excelled across all testing parameters, once again demonstrating Seraphim's exceptional product quality and strong brand reputation.
This recognition serves as a trusted benchmark for financiers, developers, and system operators, providing authoritative guidance for decision-making. Seraphim's demonstrated reliability ensures consistent power output and lower operational costs while enhancing project investment returns, thereby strengthening commercial viability and competitive edge in the global market. Tristan Erion-Lorico, Vice President of Kiwa PVEL, commented: "Seraphim modules' exceptional resilience under rigorous testing conditions sets a new benchmark for the industry. We are delighted to see Seraphim once again achieve 'Top Performer' status. Their relentless commitment to quality and reliability is helping to push the boundaries of PV technology across the industry."
Mr. Polaris Li, Chairman of Seraphim, expressed his gratitude: "We are honored to receive the 'Top Performer' from Kiwa PVEL. This achievement is the common result of all team's dedication and the professional recognition from Kiwa PVEL. As a pioneer in the industry, we remain committed to advancing technological innovation and delivering high-quality solutions that drive sustainable value for our global clients. This award not only acknowledges our past efforts but also motivates us to keep moving forward. Seraphim will continue to advance our technology and enhance our product performance, delivering even more efficient and reliable PV modules for our customers worldwide."
With 14 years of expertise in PV module manufacturing, Seraphim has remained committed to delivering superior quality. Moving forward, Seraphim will continue to build reliable module products for diverse applications through technological innovation, iterative R&D, and rigorous production processes—creating greater value for global customers and contributing to the global carbon neutrality goals.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
3 hours ago
- Korea Herald
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
• Successful validation of payloaded anti-colibactin toxin phage using IMPA ™ technology • Demonstrated ' Dual-target Therapeutic Strategy ' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular concern. This bacterium produces a toxic substance in the intestine that causes DNA damage (ICLs, Interstrand Cross-Links), which leads to DSBs (Double Strand Breaks), and has been shown in numerous studies, including Nature (2023), to increase the risk of colorectal cancer over time. Amid this situation, as an innovative bacteriophage technology development company, iNtRON Bio proposes a new possibility for microbiome-based anticancer drugs in treating colorectal cancer—considered a hard-to-treat disease—by applying our phage engineering technology called IMPA™. iNtRON Bio has been developing PHAGERIA Ⓡ, an immunotherapeutic targeting gut bacteria, and through the IMPA™ phage engineering technology developed in-house, iNtRON Bio has secured a new drug candidate payloaded with a substance that effectively eliminates colibactin ,a major causative agent of colorectal cancer and have filed a related US patent application. The phage engineering technology IMPA™ (Intelligent Modular Phage Assembly) was formerly known as the "robot bacteriophage." With the recent US patent application, it was named to clearly reflect the function as a technology for engineering modular phages (mock-up phages) that can carry therapeutic payloads. This achievement is the result of combining transposon mutagenesis, CRISPR/Cas-based forward/reverse genetics, and AI-driven analysis capabilities to explore the possibility of delivering various functional payloads. In particular, it is highly significant that iNtRON Bio successfully loaded a payload targeting colibactin ,deeply involved in colorectal cancer, onto the surface of the phage and, for the first time globally, confirmed its effectiveness. In other words, iNtRON Bio has demonstrated a dual-targeting therapeutic approach that not only eliminates pks+ E. coli, which is a main cause of colorectal cancer, but also neutralizes the toxin secreted by this bacterium. This includes verifying colibactin's role in cancer development, confirming the suppressive effect of modular phage on colorectal cancer, and proving the phage's colibactin-degrading ability—resulting in successful proof-of-concept studies and related patent acquisition. Simply put, the core of this development is that a colibactin-degrading protein was applied as a payload on the phage's protein shell, known as the capsid. Like a precision-guided missile with a warhead, the engineered phage specifically infects pks+ E. coli, kills the bacteria, and at the same time removes the colibactin toxin already secreted by the bacterium using the enzyme carried in the capsid—offering a dual therapeutic effect. Recently, the field of bacteriophage engineering is gaining attention globally. IMPA™ technology is not only a unique platform technology differentiated from other companies, but also serves as strong evidence that it can function as an actual drug delivery platform beyond simple research use. It is encouraging that iNtRON Bio's research has overcome key limitations of conventional phage-based technologies, such as decreased payload activity and phage structural instability when therapeutic substances are loaded. By confirming that the payload retains its original function, iNtRON Bio has demonstrated that it has successfully overcome high technical hurdles. The engineered phages are not merely for research purposes but were selected and validated through multiple tests with real-world and human applications in mind. iNtRON Bio has applied an advanced AI-driven optimization platform technology, refined it with great care, and plan to extend its application to other development fields for ongoing innovation. This achievement is not only a remarkable advancement in phage engineering technology but will also become a driving force for discovering innovative microbiome drug candidates through integration with other phage-based platform technologies of iNtRON Bio. It will proceed smoothly with preclinical studies including proof-of-concept (PoC) testing for combination effects with existing colorectal cancer therapies. In addition, IMPA™ phage engineering technology will be applied more broadly to ADC drug development, anti-cancer agent, and vaccines, as iNtRON Bio continues to strengthen our global technological competitiveness in these fields.
Korea Herald
3 hours ago
- Korea Herald
Precision-Matched Meat Sourcing: The Global Advantage at FHC2025
SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- FHC Shanghai Global Food Trade Show, Asia's flagship international food trade fair, returns to the Shanghai New International Expo Centre (SNIEC) from November 12-14, 2025. China's Visa Policy Opens Doors for Global Meat Commerce Leveraging China's expansive visa-free access for 54 nations, FHC2025 presents an unrivaled opportunity for the international meat industry. Suppliers and buyers gain frictionless entry for pivotal 15-day business engagements. Exhibitors enjoy expedited entry with invitations and 24-hour visa-on-arrival at key ports like Shanghai. Discover the Future of Meat at Asia's Premier Food Epicenter Occupying 200,000 sqm, FHC2025 spotlights the meat sector, building on 2024's resounding success (171,828 trade visitors, 3,000+ global exhibitors). Dedicated showcases from leading meat nations will be unveiled. Expect robust participation from international pavilions representing key players like Brazil, the USA, the EU, and Australia. Witness the convergence of global trends: premium and specialty cuts, sustainable sourcing and traceability solutions, advanced processing technologies, and the booming ready-to-eat/cook segments, all within Shanghai. Precision-Matched Connections with High-Value Meat Buyers The globally acclaimed FHC Hosted Buyer Program offers meat suppliers priority access to high-value procurement channels. Participants gain: Guaranteed High-Impact Meetings: Secure 50+ pre-vetted appointments with premium hotel procurement directors, chain restaurant central kitchen heads, and specialized meat importers. Direct Access to Decision Makers: Engage F&B association leaders and hospitality group executives face-to-face, slashing negotiation cycles by 60%. Actionable Market Intelligence: Gain critical insights into China's $150 billion meat market dynamics and evolving import regulations. VIP Advantage: Enjoy all VIP benefits including access to the VIP Lounge, welcome package and accommodation during the exhibition period (Only for VIP delegations).
Korea Herald
4 hours ago
- Korea Herald
TSH Biopharm Honored for Social Empowerment and Green Leadership at the Asia Responsible Enterprise Awards 2025
BANGKOK, Aug. 4, 2025 /PRNewswire/ -- TSH Biopharm Corporation Ltd. has been recognized with dual honors at the Asia Responsible Enterprise Awards 2025, receiving accolades for the Green Leadership and Social Empowerment categories. The awards reflect the company's growing influence as a purpose-driven pharmaceutical firm that integrates sustainability and human well-being into its corporate DNA. TSH Biopharm's Green Leadership accolade celebrates its signature initiative, "Sowing with Heart," which redefines the connection between health and the environment. In a pioneering effort, the company partnered with organic farmers in Miaoli's Formosan leopard cat conservation area, supporting pesticide-free rice cultivation. The harvested rice is transformed into thoughtfully crafted gift sets—ranging from fermented rice beverages to eco-friendly soap products—whose proceeds are donated in full to elder care organizations. By uniting biodiversity protection, local farming, and public health, TSH Biopharm demonstrates that environmental stewardship can be deeply human at its core. Equally impactful is the company's award-winning "Empowered Journeys" initiative, which earned it recognition for Social Empowerment. Launched in collaboration with the Old Five Old Foundation, the program operates mobile grocery trucks that serve isolated seniors in Taiwan's rural regions. Unlike traditional charity models, this service restores autonomy by allowing elders to choose their own supplies. With TSH Biopharm employees volunteering as delivery companions, the initiative extends beyond material support, offering emotional connection and dignity to the elderly—an approach that reshapes how businesses engage with aging populations. The success of both programs highlights TSH Biopharm's long-standing commitment to values-driven leadership. Its environmental project rejuvenates fallow land and raises public awareness about endangered species, while its social initiative brings healthcare philosophy into daily life, affirming that true wellness can flourish with community support. As TSH Biopharm continues to evolve, it remains steadfast in its mission: to build a future where healthcare is not only about treatment, but also about creating harmony between people and the planet. PR Newswire is the official news distribution partner of the Asia Responsible Enterprise Awards 2025. About Enterprise Asia Enterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine toward sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs, and other organizations to promote competitiveness and entrepreneurial development, uplifting the economic status of people across Asia and ensuring a legacy of hope, innovation, and courage for future generations. Please visit for more information. The Asia Responsible Enterprise Awards program recognizes and honors Asian businesses for championing sustainable and responsible entrepreneurship in the categories of Green Leadership, Investment in People, Health Promotion, Social Empowerment, Corporate Governance, Circular Economy Leadership, Corporate Sustainability Reporting, and Responsible Business Leadership. For more information, visit
